The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL

OMB 3235-Number: 0076

Estimated average

burden

hours per response:

4.00

1. Issuer's Identity

CIK (Filer ID Number)

Previous X None **Names**

Entity Type

Limited Liability Company

Limited Partnership

General Partnership

Business Trust

Other (Specify)

X Corporation

0001697532

Name of Issuer

Applied Therapeutics Inc.

Jurisdiction of

Incorporation/Organization

DELAWARE Year of Incorporation/Organization

Over Five Years Ago

X Within Last Five Years (Specify Year) 2016

Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer

Applied Therapeutics Inc.

Street Address 2 Street Address 1

545 5th Avenue, Suite 1400

State/Province/Country ZIP/PostalCode **Phone Number of Issuer** City

NEW YORK 10173 212-220-9226 New York

3. Related Persons

Last Name First Name Middle Name

Shendelman Shoshana

> **Street Address 1 Street Address 2**

545 5th Avenue, Suite 1400

State/Province/Country ZIP/PostalCode City

New York **NEW YORK** 10173

Relationship: X Executive Officer X Director Promoter

Clarification of Response (if Necessary):

President, CEO and Chair of the Board of Directors

Last Name First Name Middle Name

Perfetti Riccardo

> **Street Address 1 Street Address 2**

545 5th Avenue, Suite 1400

ZIP/PostalCode City State/Province/Country

New York **NEW YORK** 10173

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Chief Medical Officer

Last Name First Name Middle Name

Vignola Mark

Street Address 1 Street Address 2

545 5th Avenue, Suite 1400

City State/Province/Country ZIP/PostalCode

New York NEW YORK 10173

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Chief Financial Officer

Last Name First Name Middle Name

Funtleyder Les

Street Address 1 Street Address 2

545 5th Avenue, Suite 1400

City State/Province/Country ZIP/PostalCode

New York NEW YORK 10173

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Kanter Stacy J.

Street Address 1 Street Address 2

545 5th Avenue, Suite 1400

City State/Province/Country ZIP/PostalCode

New York NEW YORK 10173

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Lerner Teena

Street Address 1 Street Address 2

545 5th Avenue, Suite 1400

City State/Province/Country ZIP/PostalCode

New York NEW YORK 10173

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Marcus Joel S.

Street Address 1 Street Address 2

545 5th Avenue, Suite 1400

City State/Province/Country ZIP/PostalCode

New York NEW YORK 10173

Relationship: Executive Officer X Director Promoter

Last Name First Name Middle Name

S. Skyler Jay

> **Street Address 1 Street Address 2**

545 5th Avenue, Suite 1400

State/Province/Country ZIP/PostalCode City

NEW YORK New York 10173

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

4. Industry Group

Investing

Energy

5. Issuer Size

Agriculture Health Care Retailing Banking & Financial Services X Biotechnology Restaurants

Commercial Banking Health Insurance Technology Insurance Hospitals & Physicians Computers

Pharmaceuticals **Telecommunications Investment Banking** Pooled Investment Fund Other Health Care Other Technology

Is the issuer registered as Manufacturing Travel

an investment company under Real Estate Airlines & Airports the Investment Company

Commercial Act of 1940? **Lodging & Conventions** Construction Yes Nο Tourism & Travel Services

Other Banking & Financial Services **REITS & Finance** Other Travel

Business Services Residential Other

Other Real Estate Coal Mining

Electric Utilities

Environmental Services

Energy Conservation

Oil & Gas Other Energy

OR **Revenue Range Aggregate Net Asset Value Range**

No Revenues No Aggregate Net Asset Value

\$1 - \$5,000,000 \$1 - \$1,000,000

\$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$5,000,001 -\$25,000,001 - \$50,000,000 \$25,000,000

\$25,000,001 -\$50,000,001 - \$100,000,000 \$100,000,000

Over \$100,000,000 Over \$100,000,000 X Decline to Disclose Decline to Disclose Not Applicable Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

Rule 504(b)(1) (not (i), (ii) or (iii)) Investment Company Act Section 3(c) Rule 504 (b)(1)(i) Section 3(c)(1)Section 3(c)(9)Rule 504 (b)(1)(ii) Section 3(c)(2)Section 3(c)(10)Rule 504 (b)(1)(iii) X Rule 506(b) Section 3(c)(3)Section 3(c)(11) Rule 506(c) Section 3(c)(4)Section 3(c)(12)

Securities Act Section 4(a)(5) Section 3(c)(5)Section 3(c)(13)Section 3(c)(6) Section 3(c)(14) Section 3(c)(7)7. Type of Filing X New Notice Date of First Sale 2019-11-07 First Sale Yet to Occur Amendment 8. Duration of Offering Does the Issuer intend this offering to last more than one year? Yes X No 9. Type(s) of Securities Offered (select all that apply) **Pooled Investment Fund Interests** X Equity Tenant-in-Common Securities Debt Option, Warrant or Other Right to Acquire Another Security Mineral Property Securities Security to be Acquired Upon Exercise of Option, Warrant or Other (describe) Other Right to Acquire Security 10. Business Combination Transaction Is this offering being made in connection with a business combination transaction, such as Yes X No a merger, acquisition or exchange offer? Clarification of Response (if Necessary): 11. Minimum Investment Minimum investment accepted from any outside investor \$0 USD 12. Sales Compensation Recipient Recipient CRD Number None John Dexter Pearson 6093501 (Associated) Broker or Dealer None (Associated) Broker or Dealer CRD Number None Collage Partners, a division of CIM Securities LLC 120852 **Street Address 1 Street Address 2** 275 Madison Avenue, 39th Floor State/Province/Country ZIP/Postal Code **NEW YORK** 10016 State(s) of Solicitation (select all that apply) All States Foreign/non-US Check "All States" or check individual States

City

New York

CALIFORNIA ILLINOIS NEW YORK TEXAS

VIRGINIA

Recipient Recipient CRD Number X None

N/A None

(Associated) Broker or Dealer None (Associated) Broker or Dealer CRD Number None

Cowen and Company, LLC 7616

Street Address 1 Street Address 2

599 Lexington Avenue, 20th Floor

State/Province/Country ZIP/Postal Code City

New York NEW YORK 10022

State(s) of Solicitation (select all that apply) Check "All States" or check individual States

All States

Foreign/non-US

CALIFORNIA

ILLINOIS

MASSACHUSETTS

NEW YORK

VIRGINIA

Recipient CRD Number X None

N/A None

(Associated) Broker or Dealer None (Associated) Broker or Dealer CRD Number None

UBS Securities LLC 7654

Street Address 1 Street Address 2

1285 Avenue of the Americas

City State/Province/Country ZIP/Postal Code

New York NEW YORK 10019

State(s) of Solicitation (select all that apply)
Check "All States" or check individual States

All States Foreign/non-US

CALIFORNIA

ILLINOIS

MASSACHUSETTS

NEW YORK

VIRGINIA

13. Offering and Sales Amounts

Total Offering Amount \$20,014,988 USD or Indefinite

Total Amount Sold \$20,014,988 USD

Total Remaining to be Sold \$0 USD or Indefinite

Clarification of Response (if Necessary):

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering. Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

12

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$1,250,449 USD X Estimate

Finders' Fees \$0 USD Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Applied Therapeutics Inc.	/s/ Mark Vignola	Mark Vignola	Chief Financial Officer	2019-11-21

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.